Viridian Therapeutics price target lowered to $36 from $40 at Truist [Yahoo! Finance]
Viridian Therapeutics, Inc. (VRDN)
Company Research
Source: Yahoo! Finance
Reactivity to regulatory and policy shifts across the sector continues to ease, and the firm also notes a recent pickup in deal activity, which has the potential to build momentum through the remainder of the year into mid-terms, the analyst tells investors in a research note. For the company, the firm notes that while it has slightly tempered its ultimate expectations on Viridian's commercial opportunity in TED, with Veli' peaking at $630M in 2031, and Ele' peaking at $1.14B in 2035, the debate is likely to continue as investors and even docs balance the real-world utility of Viridian's reduced therapeutic burden value prop with Amgen's ( AMGN ) existing doc, patient, and payer relationships and existing commercial infrastructure and support, Truist added. Easter Sale - 70% Off TipRanks Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Pick
Show less
Read more
Impact Snapshot
Event Time:
VRDN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VRDN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VRDN alerts
High impacting Viridian Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
VRDN
News
- Viridian Therapeutics (VRDN) had its price target lowered by Wedbush from $37.00 to $31.00. They now have an "outperform" rating on the stock.MarketBeat
- A Look At Viridian Therapeutics (VRDN) Valuation After A Sharp Multi-Month Share Price Pullback [Yahoo! Finance]Yahoo! Finance
- Viridian Therapeutics (VRDN) had its price target lowered by The Goldman Sachs Group, Inc. from $36.00 to $31.00. They now have a "buy" rating on the stock.MarketBeat
- Viridian Therapeutics (VRDN) had its price target lowered by Royal Bank Of Canada from $42.00 to $30.00. They now have an "outperform" rating on the stock.MarketBeat
- Viridian Therapeutics, Inc. (VRDN) Discusses Positive Topline Results from Elegrobart REVEAL-1 Phase III Trial in Active Thyroid Eye Disease Transcript [Seeking Alpha]Seeking Alpha
VRDN
Earnings
- 2/26/26 - Miss
VRDN
Sec Filings
- 4/17/26 - Form ARS
- 4/17/26 - Form DEFA14A
- 4/17/26 - Form DEF
- VRDN's page on the SEC website